A randomized multicenter phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab (anti-PD1) to CRT alone in patients with resectable or borderline resectable pancreatic cancer.

被引：0

作者：

Katz, Matthew H. G.

Bauer, Todd W.

Varadhachary, Gauri R.

Petroni, Gina R.

Bullock, Timothy

Slingluff, Craig L.

Rahma, Osama E.

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Virginia, Dept Surg, Charlottesville, VA USA

[3] Univ Virginia Hlth Syst, Charlottesville, VA USA

[4] Univ Virginia, Charlottesville, VA USA

[5] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA

来源：

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.tps3098

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS3098

引用

页数：1